(Alliance News) - Arecor Therapeutics PLC on Wednesday said its subsidiary Tetris Pharma Ltd has launched its Olguo treatment in Austria, the second European launch in its European roll-out strategy.

The Essex, England-based biopharmaceutical company said the launch builds on the roll-out of Ogluo in Germany and the UK, as part of Tetris Pharma's pan-European commercialisation programme.

Ogluo is a glucagon prefilled autoinjector pen used a s a treatment for severe hypoglycaemia in children and adults living with diabetes. Arecor said there are around 450,000 adults with diabetes in Austria.

The company said it is in discussions with a number of health authorities across Europe "to ensure timely launches in additional major European countries".

Tetris Pharma Managing Director Shafiq Choudhary said: "In Austria, people living with diabetes will now be able to receive Ogluo to tackle severe hypoglycaemic events, enabling patients and those around to them to act quickly when such an event happens,

"With this launch in Austria, we look forward to expanding our reach within Europe over the coming months to bring this new treatment to people living with diabetes," he said.

Arecor shares were 7.5% higher at 258.00 pence per share on Wednesday morning in London.

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.